Vita Life Sciences Limited · ASX:VLS
Vita Life Sciences — Shareholder Meeting (May 2024)
26 slides from Vita Life Sciences's shareholder meeting presentation, May 22, 2024
Slide 1: Annual General Meeting
Annual General Meeting 22 May 2024
Slide 2: Agenda
Agenda 1. CHAIRMAN’S WELCOME ADDRESS 2. MANAGING DIRECTOR’S REVIEW 3. ORDINARY RESOLUTIONS 4. QUESTIONS & ANSWERS
Slide 3: Henry Townsing, Chairman
Henry Townsing Chairman Mr Townsing brings over 30 years’ experience in corporate finance and private equity. He was a Director of the Company, from 1985 to 1992, 2004 to 2009 and was reappointed a Director on 22nd December 2011. Mr Townsing was appointed as the Chairman of the Company effective 28t
Slide 4: Agenda
Agenda 1. CHAIRMAN’S WELCOME ADDRESS 2. MANAGING DIRECTOR’S REVIEW 3. ORDINARY RESOLUTIONS 4. QUESTIONS & ANSWERS
Slide 5: Andrew O'Keefe, Managing Director
Andrew O’Keefe Managing Director Mr O’Keefe was appointed Managing Director on 1st January 2017. Prior to his Managing Director appointment, Mr O’Keefe was the Chief Executive Officer of Herbs of Gold Australia. He has over 20 years’ experience within the Australian pharmaceutical and healthcare ind
Slide 6: A Snapshot of the Vita Life Sciences Group
A Snapshot of the Vita Life Sciences Group One of Australia’s & South East AUD74M+ in annual net High quality standards in sourcing & Over 350+ premium healthcare & Over 400 employees Asia’s leading natural healthcare revenue; strong balance sheet manufacturing pharmaceutical products across Austral
Slide 7: Financial Performance
Financial Performance BALANCE SHEET RECORD SALES PRE-TAX PROFIT EQUITY DIVIDEND PAYMENT $74.2M, UP 11% $12.5M, UP 16% 9.00 CENTS/SHARE, $43.3M,NET CASH $24.6M UP 50% (WITHOUT ANY BORROWINGS) ANNUAL GENERAL MEETING 2024
Slide 8: Global Performance and footprint
Global Performance and footprint Other Asia 2% Australia 59% $1.6M $43.5M Singapore 8% $6.3M Asia 41% 2023 revenue by geography Malaysia 31% $22.8M ANNUAL GENERAL MEETING 2024
Slide 9: Our awards
Our awards Australia Malaysia Singapore VOICE OF THE CUSTOMER BEST BRAND SINGAPORE CONSUMERS’ CHOICE 2023/2024 ADVANTAGE PHARMACY PROGRAM 2023 STAR OUTSTANDING BUSINESS AWARDS 2023 SINGAPORE MARKETING EXCELLENCE AWARD 2023 BEST COMPLEMENTARY MEDICINE BRAND MOST WANTED SUPPLEMENT FOR SKIN BRIGHTENING
Slide 10: Vietnam market launch
Vietnam market launch ANNUAL GENERAL MEETING 2024
Slide 11: Marketing Reach
Marketing Reach ANNUAL GENERAL MEETING 2024
Slide 12: Strategic priorities
Strategic priorities Our pillars EDUCATION STRATEGIC OPERATIONAL BRANDBUILDING & INNOVATION PARTNERSHIPS LEVERAGE Key initiatives to support our pillars CONTINUATION OF LAUNCH OF OUR NEW CONSUMER LED INVESTEMENT BACK NEWBUSINESS EXISTING CHANNEL TRAINING PORTAL FOR PRODUCT INTO FUTURE GROWTH NEWPROD
Slide 13: Outlook
-Driving brand performance across our respective markets will be paramount to the ongoing business trajectory -Our product proposition and channel strategies across our respective markets remains robust Outlook - The business continues to track well against expectations in FY24 -Management remains c
Slide 14: Annual General Meeting 2024
ANNUAL GENERAL MEETING 2024
Slide 15: Agenda
Agenda 1. CHAIRMAN’S WELCOME ADDRESS 2. MANAGING DIRECTOR’S REVIEW 3. ORDINARY RESOLUTIONS 4. QUESTIONS & ANSWERS ANNUAL GENERAL MEETING 2024
Slide 16: Resolutions
Resolutions 1. Remuneration Report 2. Re-election of Director – Jack Teoh 3. Re-election of Director- Peter Osborne 4. Share buy back 5. Approval to replace Constitution (Special) 6. Long Term Incentive Plan 7. Long Term Incentive Plan: Grant of a limited recourse loan to a Director to purchase ordi
Slide 17: Proxy-Resolution 1
Proxy-Resolution 1 PROXY’S RESOLUTIONS IN FAVOUR AGAINST EXCLUDED DISCRETION 1 Adoption of the Remuneration Report 4,649,562 73,522 22,739,245 9,673,293 ANNUAL GENERAL MEETING 2024
Slide 18: Proxy-Resolution 2
Proxy-Resolution 2 PROXY’S RESOLUTIONS IN FAVOUR AGAINST EXCLUDED DISCRETION Re-election of Director 2 14,398,666 26,064 22,739,245 0 (Jack Teoh) ANNUAL GENERAL MEETING 2024
Slide 19: Proxy-Resolution 3
Proxy-Resolution 3 PROXY’S RESOLUTIONS IN FAVOUR AGAINST EXCLUDED DISCRETION Re-election of Director 3 14,402,815 21,915 22,739,245 0 (Peter Osborne) ANNUAL GENERAL MEETING 2024
Slide 20: Proxy-Resolution 4
Proxy-Resolution 4 PROXY’S RESOLUTIONS IN FAVOUR AGAINST EXCLUDED DISCRETION 4 Share buy-back 14,386,559 34,395 22,739,728 0 ANNUAL GENERAL MEETING 2024
Slide 21: Proxy-Resolution 5 (Special)
Proxy-Resolution 5 (Special) PROXY’S RESOLUTIONS IN FAVOUR AGAINST EXCLUDED DISCRETION 5 Approval to replace Constitution 14,378,008 34,901 22,739,728 0 ANNUAL GENERAL MEETING 2024
Slide 22: Proxy-Resolution 6
Proxy-Resolution 6 PROXY’S RESOLUTIONS IN FAVOUR AGAINST EXCLUDED DISCRETION 6 Long Term Incentive Plan 4,652,766 71,335 22,739,245 9,673,293 ANNUAL GENERAL MEETING 2024
Slide 23: Proxy-Resolution 7
Proxy-Resolution 7 PROXY’S RESOLUTIONS IN FAVOUR AGAINST EXCLUDED DISCRETION Long Term Incentive Plan: Grant of a 7 limited recourse loan to a Director to 4,643,199 80,152 22,739,728 9,673,293 purchase ordinary shares ANNUAL GENERAL MEETING 2024
Slide 24: Proxy
Proxy PROXY’S RESOLUTIONS IN FAVOUR AGAINST EXCLUDED DISCRETION 1 Adoption of the Remuneration Report 4,649,562 73,522 22,739,245 9,673,293 Re-election of Director 2 14,398,666 26,064 22,739,245 0 (Jack Teoh) Re-election of Director 3 14,402,815 21,915 22,739,245 0 (Peter Osborne) 4 Share buy-back 1
Slide 25: Agenda
Agenda 1. CHAIRMAN’S WELCOME ADDRESS 2. MANAGING DIRECTOR’S REVIEW 3. ORDINARY RESOLUTIONS 4. QUESTIONS & ANSWERS ANNUAL GENERAL MEETING 2024
Slide 26: Disclaimer
Disclaimer This document has been prepared by Vita Life Sciences Limited (Vita Life Sciences) and comprises written material/slides for a presentation concerning Vita Life Sciences. The presentation is for information purposes only and does not constitute or form part of any offer or invitation to a